Placebo + SIM

Phase 2Terminated
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liver Fibrosis Due to NASH

Conditions

Liver Fibrosis Due to NASH

Trial Timeline

Oct 29, 2012 → Jan 3, 2017

About Placebo + SIM

Placebo + SIM is a phase 2 stage product being developed by Gilead Sciences for Liver Fibrosis Due to NASH. The current trial status is terminated. This product is registered under clinical trial identifier NCT01672879. Target conditions include Liver Fibrosis Due to NASH.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT01672866Phase 2Terminated
NCT01672879Phase 2Terminated

Competing Products

20 competing products in Liver Fibrosis Due to NASH

See all competitors
ProductCompanyStageHype Score
LanifibranorInventivaPhase 2
47
GODEX + PlaceboCelltrionPhase 3
77
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
TacrolimusAstellas PharmaPre-clinical
23
ATG (Fresenius Biotech)Astellas PharmaPhase 2
52
Advagraf + Prograf + PrografAstellas PharmaApproved
85
Prograf + AdvagrafAstellas PharmaApproved
85
ADVAGRAF®Astellas PharmaApproved
85
Prograf + MR4Astellas PharmaPhase 3
77
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
52
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 3
77
Prograf-XL + Prograf + MMFAstellas PharmaPhase 3
77
micafungin + fluconazole + liposomal amphotericin B + caspofunginAstellas PharmaPhase 3
77
Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
85
FK506E (modified release tacrolimus) + Prograf (tacrolimus)Astellas PharmaPhase 3
77
FK778Astellas PharmaPhase 2
52
Tacrolimus modified-release + PrografAstellas PharmaPhase 3
77
Advagraf + PrografAstellas PharmaApproved
85